Human cytomegalovirus expands a CD8

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

45 citing papers in PubMed.

1. Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation.Haematologica · 2022
   Trial
2. NKG2A-HLA-E axis contributes to an immunosuppressive checkpoint network in hepatocellular carcinoma.Journal for immunotherapy of cancer · 2026
   Article
3. NK-like and networked CD8bioRxiv : the preprint server for biology · 2026
   Article
4. Single-cell transcriptomics reveals pediatric immune responses to COVID-19 vaccination.iScience · 2026
   Article
5. Fetal and Neonatal Immune Response to Congenital Cytomegalovirus (cCMV) Infection: A Systematically Conducted Scoping Review.Viruses · 2026
   Article
6. The Long Shadow of Early HCMV-HIV Coinfection: Epidemiology, Pathogenesis, and Immune Consequences.Children (Basel, Switzerland) · 2026
   Review
7. Cancer viroimmunotherapy platforms based on varicella-zoster virus and cytomegalovirus.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
   Review
8. Antigen-experienced NK-T cells: integrating new insights and exploring therapeutic potential in cancer immunotherapy.Frontiers in immunology · 2026
   Review
9. Interaction between HLA-B leader peptide variants and cytomegalovirus serostatus is associated with early T cell-mediated rejection in kidney transplantation.Frontiers in immunology · 2026
   Article
10. Directly reprogrammed NK cells driven by BCL11B depletion enhance targeted immunotherapy against pancreatic ductal adenocarcinoma.Journal of hematology & oncology · 2025
    Article
11. Essential role of CD56Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
12. Innate-like memory T cells rapidly emerge in humans after gene therapy for SCID-X1.Immunity · 2025
    Article
13. BNT162b2 COVID-19 vaccination elicits the expansion of CD16The Journal of allergy and clinical immunology · 2025
    Article
14. Coordinated immune networks in leukemia bone marrow microenvironments distinguish response to cellular therapy.Science immunology · 2025
    Article
15. Oncolytic cytomegaloviruses expressing EGFR-retargeted fusogenic glycoprotein complex and drug-controllable interleukin 12.Cell reports. Medicine · 2025
    Article
16. A vaccine against cytomegalovirus: how close are we?The Journal of clinical investigation · 2025
    Article
17. Neonatal T cells unleash innate powers to combat congenital cytomegalovirus infection.The Journal of clinical investigation · 2025
    Article
18. Leveraging innate immune signals in CD8+ T cells to boost antitumor immunity.Frontiers in immunology · 2025
    Review
19. In utero human cytomegalovirus infection expands NK-like FcγRIII+CD8+ T cells that mediate Fc antibody functions.The Journal of clinical investigation · 2024
    Article
20. Polygenic polymorphism is associated with NKG2A repertoire and influences lymphocyte phenotype and function.Blood advances · 2024
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

10 authors.

Funding

Abstract

Indexed as